Share Price and Basic Stock Data
Last Updated: December 25, 2025, 3:44 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Themis Medicare Ltd operates within the pharmaceuticals industry, focusing on the development and manufacturing of various medicinal products. As of the latest reporting period, the company’s share price stood at ₹103 with a market capitalization of ₹948 Cr. Over the past few quarters, Themis has experienced fluctuating sales figures, with a high of ₹105 Cr in September 2023 and a low of ₹80 Cr in March 2023. The annual sales for FY 2025 are reported at ₹406 Cr, a slight rise from ₹382 Cr in FY 2024, indicating a modest growth trajectory. However, when compared to its peak sales of ₹395 Cr in FY 2022, it is evident that the company has not yet returned to its previous highs. This inconsistency in revenue generation suggests challenges in maintaining market demand or operational efficiency. The trailing twelve months (TTM) sales reported were ₹341 Cr, which reflects ongoing volatility in performance.
Profitability and Efficiency Metrics
Themis Medicare’s profitability metrics present a mixed picture, with a reported net profit of ₹30 Cr for FY 2025, which is a decline from ₹44 Cr in FY 2024 and ₹57 Cr in FY 2023. This downward trend highlights the challenges the company faces in managing its operating costs effectively. The operating profit margin (OPM) for the latest fiscal year was 12%, a decrease from 13% in FY 2024, indicating potential inefficiencies or rising costs. The interest coverage ratio (ICR) stood at 5.35x, suggesting that the company can comfortably meet its interest obligations, but the overall return on equity (ROE) is low at 7.65%, which is below the sector average, indicating that shareholder returns are not maximized. The cash conversion cycle (CCC) is reported at 250 days, which is relatively high and implies inefficiencies in asset management, particularly in inventory and receivables.
Balance Sheet Strength and Financial Ratios
The balance sheet of Themis Medicare reflects a total assets value of ₹588 Cr, with total liabilities at ₹588 Cr as well, indicating the company is currently managing a balanced approach to its capital structure. The reserves of ₹393 Cr signify a solid buffer for future investments or operational challenges. Borrowings are reported at ₹96 Cr, representing a manageable debt level, translating to a debt-to-equity ratio of 0.20. This low ratio suggests that the company is not overly reliant on debt financing, which is a positive aspect for long-term sustainability. The price-to-book value (P/BV) ratio is noted at 3.35x, indicating a premium over the book value, which could reflect investor confidence or expectations of future growth. However, the return on capital employed (ROCE) at 10.4% remains below optimal levels, suggesting room for improvement in capital efficiency.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Themis Medicare reveals that promoters hold a significant 67.15% stake, indicating strong control over the company. The presence of institutional investors is minimal, with foreign institutional investors (FIIs) holding only 0.06% and domestic institutional investors (DIIs) at 0.01%. This low level of institutional interest may raise concerns regarding the broader market perception of the company. The public segment holds 32.77% of shares, amounting to approximately 22,490 shareholders, which shows a diverse retail investor base. The increase in the number of shareholders from 6,362 in December 2022 to 22,490 by September 2025 reflects growing interest, but the overall low institutional participation may limit liquidity and support for the stock price in volatile conditions.
Outlook, Risks, and Final Insight
The outlook for Themis Medicare is contingent on its ability to stabilize sales and enhance operational efficiency. Key strengths include a solid reserve base of ₹393 Cr and manageable debt levels, which provide a buffer for navigating financial challenges. However, risks such as declining profitability, high cash conversion cycles, and minimal institutional interest could impede growth. The company must prioritize strategies to improve its margins and operational efficiency to attract institutional investors and enhance shareholder value. In scenarios where sales growth accelerates and costs are managed effectively, Themis could position itself favorably in the market. Conversely, failure to address operational inefficiencies may lead to further declines in profitability, ultimately affecting investor confidence and market performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 135 Cr. | 107 | 231/84.3 | 29.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,770 Cr. | 438 | 479/192 | 98.8 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 48.7 Cr. | 33.3 | 35.0/17.0 | 116 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,181.97 Cr | 1,153.40 | 53.07 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 94 | 91 | 89 | 80 | 97 | 105 | 83 | 98 | 123 | 117 | 94 | 72 | 98 |
| Expenses | 74 | 70 | 74 | 70 | 75 | 92 | 74 | 89 | 94 | 100 | 88 | 79 | 108 |
| Operating Profit | 20 | 21 | 15 | 10 | 22 | 12 | 8 | 9 | 29 | 17 | 6 | -8 | -10 |
| OPM % | 22% | 23% | 17% | 13% | 22% | 12% | 10% | 10% | 24% | 15% | 6% | -11% | -10% |
| Other Income | 6 | 6 | 7 | 5 | 6 | 7 | 6 | 5 | 7 | 6 | 1 | 2 | 1 |
| Interest | 2 | 2 | 2 | 3 | 2 | 2 | 3 | 2 | 2 | 2 | 3 | 2 | 2 |
| Depreciation | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 3 | 3 | 3 |
| Profit before tax | 22 | 23 | 18 | 10 | 23 | 14 | 8 | 9 | 31 | 18 | 2 | -11 | -14 |
| Tax % | 21% | 21% | 24% | 18% | 19% | 19% | 10% | 24% | 21% | 20% | 69% | -13% | 1% |
| Net Profit | 17 | 18 | 13 | 8 | 18 | 11 | 7 | 7 | 25 | 14 | 1 | -10 | -14 |
| EPS in Rs | 1.89 | 1.93 | 1.45 | 0.91 | 1.98 | 1.23 | 0.80 | 0.72 | 2.68 | 1.55 | 0.06 | -1.05 | -1.54 |
Last Updated: August 20, 2025, 2:15 am
Below is a detailed analysis of the quarterly data for Themis Medicare Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 98.00 Cr.. The value appears strong and on an upward trend. It has increased from 72.00 Cr. (Mar 2025) to 98.00 Cr., marking an increase of 26.00 Cr..
- For Expenses, as of Jun 2025, the value is 108.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 79.00 Cr. (Mar 2025) to 108.00 Cr., marking an increase of 29.00 Cr..
- For Operating Profit, as of Jun 2025, the value is -10.00 Cr.. The value appears to be declining and may need further review. It has decreased from -8.00 Cr. (Mar 2025) to -10.00 Cr., marking a decrease of 2.00 Cr..
- For OPM %, as of Jun 2025, the value is -10.00%. The value appears strong and on an upward trend. It has increased from -11.00% (Mar 2025) to -10.00%, marking an increase of 1.00%.
- For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
- For Depreciation, as of Jun 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -14.00 Cr.. The value appears to be declining and may need further review. It has decreased from -11.00 Cr. (Mar 2025) to -14.00 Cr., marking a decrease of 3.00 Cr..
- For Tax %, as of Jun 2025, the value is 1.00%. The value appears to be increasing, which may not be favorable. It has increased from -13.00% (Mar 2025) to 1.00%, marking an increase of 14.00%.
- For Net Profit, as of Jun 2025, the value is -14.00 Cr.. The value appears to be declining and may need further review. It has decreased from -10.00 Cr. (Mar 2025) to -14.00 Cr., marking a decrease of 4.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -1.54. The value appears to be declining and may need further review. It has decreased from -1.05 (Mar 2025) to -1.54, marking a decrease of 0.49.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:30 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 195 | 202 | 232 | 217 | 210 | 184 | 202 | 231 | 395 | 354 | 382 | 406 | 341 |
| Expenses | 171 | 184 | 194 | 184 | 184 | 181 | 166 | 181 | 299 | 287 | 330 | 356 | 356 |
| Operating Profit | 24 | 18 | 38 | 33 | 25 | 2 | 36 | 49 | 96 | 67 | 52 | 49 | -15 |
| OPM % | 12% | 9% | 16% | 15% | 12% | 1% | 18% | 21% | 24% | 19% | 13% | 12% | -4% |
| Other Income | 5 | 13 | 3 | 4 | 6 | 5 | 12 | 13 | 18 | 25 | 24 | 11 | 9 |
| Interest | 16 | 15 | 12 | 12 | 12 | 12 | 13 | 13 | 9 | 10 | 9 | 10 | 10 |
| Depreciation | 9 | 11 | 12 | 7 | 7 | 8 | 8 | 9 | 9 | 10 | 12 | 10 | 10 |
| Profit before tax | 4 | 5 | 17 | 18 | 11 | -13 | 27 | 41 | 95 | 73 | 53 | 40 | -27 |
| Tax % | 32% | -20% | 11% | 9% | 1% | -15% | 8% | 14% | 23% | 22% | 19% | 25% | |
| Net Profit | 3 | 6 | 16 | 16 | 11 | -11 | 25 | 36 | 73 | 57 | 44 | 30 | -27 |
| EPS in Rs | 0.32 | 0.73 | 1.91 | 1.77 | 1.23 | -1.17 | 2.70 | 3.88 | 7.92 | 6.18 | 4.73 | 3.24 | -2.92 |
| Dividend Payout % | 28% | 25% | 9% | 0% | 0% | 0% | 6% | 11% | 6% | 8% | 11% | 15% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 100.00% | 166.67% | 0.00% | -31.25% | -200.00% | 327.27% | 44.00% | 102.78% | -21.92% | -22.81% | -31.82% |
| Change in YoY Net Profit Growth (%) | 0.00% | 66.67% | -166.67% | -31.25% | -168.75% | 527.27% | -283.27% | 58.78% | -124.70% | -0.89% | -9.01% |
Themis Medicare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 15% |
| 3 Years: | 1% |
| TTM: | -7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 4% |
| 3 Years: | -25% |
| TTM: | -118% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 24% |
| 3 Years: | 8% |
| 1 Year: | -59% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 15% |
| 3 Years: | 12% |
| Last Year: | 8% |
Last Updated: September 5, 2025, 1:46 pm
Balance Sheet
Last Updated: December 4, 2025, 2:07 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Reserves | 48 | 51 | 66 | 143 | 160 | 149 | 174 | 209 | 278 | 330 | 368 | 393 | 371 |
| Borrowings | 148 | 140 | 128 | 82 | 80 | 82 | 100 | 87 | 80 | 92 | 96 | 83 | 96 |
| Other Liabilities | 79 | 77 | 73 | 54 | 56 | 74 | 67 | 65 | 61 | 82 | 93 | 102 | 107 |
| Total Liabilities | 284 | 277 | 275 | 289 | 305 | 314 | 350 | 371 | 428 | 514 | 566 | 588 | 582 |
| Fixed Assets | 121 | 122 | 117 | 124 | 126 | 123 | 116 | 133 | 144 | 162 | 168 | 172 | 169 |
| CWIP | 12 | 4 | 6 | 9 | 2 | 2 | 8 | 2 | 3 | 3 | 3 | 3 | 3 |
| Investments | 4 | 5 | 6 | 23 | 24 | 27 | 35 | 45 | 56 | 70 | 89 | 95 | 96 |
| Other Assets | 147 | 146 | 146 | 133 | 153 | 162 | 191 | 191 | 225 | 279 | 307 | 318 | 314 |
| Total Assets | 284 | 277 | 275 | 289 | 305 | 314 | 350 | 371 | 428 | 514 | 566 | 588 | 582 |
Below is a detailed analysis of the balance sheet data for Themis Medicare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 9.00 Cr..
- For Reserves, as of Sep 2025, the value is 371.00 Cr.. The value appears to be declining and may need further review. It has decreased from 393.00 Cr. (Mar 2025) to 371.00 Cr., marking a decrease of 22.00 Cr..
- For Borrowings, as of Sep 2025, the value is 96.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 83.00 Cr. (Mar 2025) to 96.00 Cr., marking an increase of 13.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 107.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 102.00 Cr. (Mar 2025) to 107.00 Cr., marking an increase of 5.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 582.00 Cr.. The value appears to be improving (decreasing). It has decreased from 588.00 Cr. (Mar 2025) to 582.00 Cr., marking a decrease of 6.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 169.00 Cr.. The value appears to be declining and may need further review. It has decreased from 172.00 Cr. (Mar 2025) to 169.00 Cr., marking a decrease of 3.00 Cr..
- For CWIP, as of Sep 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Investments, as of Sep 2025, the value is 96.00 Cr.. The value appears strong and on an upward trend. It has increased from 95.00 Cr. (Mar 2025) to 96.00 Cr., marking an increase of 1.00 Cr..
- For Other Assets, as of Sep 2025, the value is 314.00 Cr.. The value appears to be declining and may need further review. It has decreased from 318.00 Cr. (Mar 2025) to 314.00 Cr., marking a decrease of 4.00 Cr..
- For Total Assets, as of Sep 2025, the value is 582.00 Cr.. The value appears to be declining and may need further review. It has decreased from 588.00 Cr. (Mar 2025) to 582.00 Cr., marking a decrease of 6.00 Cr..
Notably, the Reserves (371.00 Cr.) exceed the Borrowings (96.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -124.00 | -122.00 | -90.00 | -49.00 | -55.00 | -80.00 | -64.00 | -38.00 | 16.00 | -25.00 | -44.00 | -34.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 74 | 82 | 75 | 81 | 120 | 145 | 186 | 123 | 93 | 149 | 170 | 159 |
| Inventory Days | 280 | 246 | 243 | 250 | 253 | 287 | 315 | 272 | 150 | 213 | 188 | 233 |
| Days Payable | 240 | 237 | 145 | 163 | 156 | 187 | 171 | 143 | 79 | 123 | 126 | 142 |
| Cash Conversion Cycle | 114 | 91 | 172 | 168 | 216 | 244 | 330 | 251 | 164 | 239 | 232 | 250 |
| Working Capital Days | -17 | -20 | -17 | -16 | 19 | -1 | 37 | 51 | 72 | 110 | 116 | 121 |
| ROCE % | 10% | 9% | 15% | 13% | 10% | -1% | 15% | 18% | 30% | 20% | 14% | 10% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 322 | 0.08 | 0.01 | 322 | 2025-04-22 17:25:18 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 3.24 | 4.73 | 61.83 | 79.22 | 38.86 |
| Diluted EPS (Rs.) | 3.24 | 4.72 | 61.73 | 79.07 | 38.84 |
| Cash EPS (Rs.) | 3.68 | 4.02 | 58.44 | 77.19 | 37.85 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 43.74 | 41.03 | 368.85 | 312.48 | 237.80 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 43.74 | 41.03 | 368.85 | 312.48 | 237.80 |
| Revenue From Operations / Share (Rs.) | 44.06 | 41.48 | 385.02 | 428.91 | 251.04 |
| PBDIT / Share (Rs.) | 5.84 | 6.11 | 85.80 | 111.06 | 57.81 |
| PBIT / Share (Rs.) | 4.76 | 4.78 | 74.39 | 100.75 | 48.50 |
| PBT / Share (Rs.) | 3.67 | 3.76 | 64.00 | 91.22 | 34.67 |
| Net Profit / Share (Rs.) | 2.60 | 2.69 | 47.03 | 66.89 | 28.54 |
| NP After MI And SOA / Share (Rs.) | 3.24 | 4.73 | 61.83 | 79.22 | 38.86 |
| PBDIT Margin (%) | 13.24 | 14.73 | 22.28 | 25.89 | 23.02 |
| PBIT Margin (%) | 10.79 | 11.52 | 19.32 | 23.49 | 19.32 |
| PBT Margin (%) | 8.32 | 9.07 | 16.62 | 21.26 | 13.81 |
| Net Profit Margin (%) | 5.89 | 6.47 | 12.21 | 15.59 | 11.37 |
| NP After MI And SOA Margin (%) | 7.35 | 11.40 | 16.05 | 18.46 | 15.47 |
| Return on Networth / Equity (%) | 7.41 | 11.52 | 16.76 | 25.35 | 16.33 |
| Return on Capital Employeed (%) | 10.13 | 10.68 | 18.26 | 29.12 | 18.35 |
| Return On Assets (%) | 5.07 | 7.68 | 11.07 | 17.03 | 9.61 |
| Long Term Debt / Equity (X) | 0.04 | 0.07 | 0.08 | 0.08 | 0.10 |
| Total Debt / Equity (X) | 0.20 | 0.25 | 0.27 | 0.27 | 0.36 |
| Asset Turnover Ratio (%) | 0.70 | 0.70 | 0.75 | 1.05 | 0.67 |
| Current Ratio (X) | 1.95 | 1.90 | 1.90 | 1.96 | 1.45 |
| Quick Ratio (X) | 1.41 | 1.44 | 1.41 | 1.40 | 0.98 |
| Inventory Turnover Ratio (X) | 5.24 | 1.21 | 1.48 | 1.90 | 1.20 |
| Dividend Payout Ratio (NP) (%) | 15.42 | 10.57 | 8.08 | 5.42 | 4.50 |
| Dividend Payout Ratio (CP) (%) | 11.57 | 8.25 | 6.82 | 4.80 | 3.63 |
| Earning Retention Ratio (%) | 84.58 | 89.43 | 91.92 | 94.58 | 95.50 |
| Cash Earning Retention Ratio (%) | 88.43 | 91.75 | 93.18 | 95.20 | 96.37 |
| Interest Coverage Ratio (X) | 5.35 | 6.00 | 8.26 | 11.64 | 4.18 |
| Interest Coverage Ratio (Post Tax) (X) | 3.38 | 3.64 | 5.53 | 8.01 | 3.06 |
| Enterprise Value (Cr.) | 1419.92 | 2092.17 | 1146.53 | 910.58 | 312.04 |
| EV / Net Operating Revenue (X) | 3.50 | 5.48 | 3.24 | 2.31 | 1.35 |
| EV / EBITDA (X) | 26.43 | 37.19 | 14.52 | 8.91 | 5.87 |
| MarketCap / Net Operating Revenue (X) | 3.33 | 5.28 | 3.03 | 2.18 | 1.12 |
| Retention Ratios (%) | 84.57 | 89.42 | 91.91 | 94.57 | 95.49 |
| Price / BV (X) | 3.35 | 5.34 | 3.16 | 2.99 | 1.18 |
| Price / Net Operating Revenue (X) | 3.33 | 5.28 | 3.03 | 2.18 | 1.12 |
| EarningsYield | 0.02 | 0.02 | 0.05 | 0.08 | 0.13 |
After reviewing the key financial ratios for Themis Medicare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 3.24. This value is below the healthy minimum of 5. It has decreased from 4.73 (Mar 24) to 3.24, marking a decrease of 1.49.
- For Diluted EPS (Rs.), as of Mar 25, the value is 3.24. This value is below the healthy minimum of 5. It has decreased from 4.72 (Mar 24) to 3.24, marking a decrease of 1.48.
- For Cash EPS (Rs.), as of Mar 25, the value is 3.68. This value is within the healthy range. It has decreased from 4.02 (Mar 24) to 3.68, marking a decrease of 0.34.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 43.74. It has increased from 41.03 (Mar 24) to 43.74, marking an increase of 2.71.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 43.74. It has increased from 41.03 (Mar 24) to 43.74, marking an increase of 2.71.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 44.06. It has increased from 41.48 (Mar 24) to 44.06, marking an increase of 2.58.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 5.84. This value is within the healthy range. It has decreased from 6.11 (Mar 24) to 5.84, marking a decrease of 0.27.
- For PBIT / Share (Rs.), as of Mar 25, the value is 4.76. This value is within the healthy range. It has decreased from 4.78 (Mar 24) to 4.76, marking a decrease of 0.02.
- For PBT / Share (Rs.), as of Mar 25, the value is 3.67. This value is within the healthy range. It has decreased from 3.76 (Mar 24) to 3.67, marking a decrease of 0.09.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.60. This value is within the healthy range. It has decreased from 2.69 (Mar 24) to 2.60, marking a decrease of 0.09.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 3.24. This value is within the healthy range. It has decreased from 4.73 (Mar 24) to 3.24, marking a decrease of 1.49.
- For PBDIT Margin (%), as of Mar 25, the value is 13.24. This value is within the healthy range. It has decreased from 14.73 (Mar 24) to 13.24, marking a decrease of 1.49.
- For PBIT Margin (%), as of Mar 25, the value is 10.79. This value is within the healthy range. It has decreased from 11.52 (Mar 24) to 10.79, marking a decrease of 0.73.
- For PBT Margin (%), as of Mar 25, the value is 8.32. This value is below the healthy minimum of 10. It has decreased from 9.07 (Mar 24) to 8.32, marking a decrease of 0.75.
- For Net Profit Margin (%), as of Mar 25, the value is 5.89. This value is within the healthy range. It has decreased from 6.47 (Mar 24) to 5.89, marking a decrease of 0.58.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.35. This value is below the healthy minimum of 8. It has decreased from 11.40 (Mar 24) to 7.35, marking a decrease of 4.05.
- For Return on Networth / Equity (%), as of Mar 25, the value is 7.41. This value is below the healthy minimum of 15. It has decreased from 11.52 (Mar 24) to 7.41, marking a decrease of 4.11.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.13. This value is within the healthy range. It has decreased from 10.68 (Mar 24) to 10.13, marking a decrease of 0.55.
- For Return On Assets (%), as of Mar 25, the value is 5.07. This value is within the healthy range. It has decreased from 7.68 (Mar 24) to 5.07, marking a decrease of 2.61.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 0.2. It has decreased from 0.07 (Mar 24) to 0.04, marking a decrease of 0.03.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.20. This value is within the healthy range. It has decreased from 0.25 (Mar 24) to 0.20, marking a decrease of 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.70. There is no change compared to the previous period (Mar 24) which recorded 0.70.
- For Current Ratio (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.90 (Mar 24) to 1.95, marking an increase of 0.05.
- For Quick Ratio (X), as of Mar 25, the value is 1.41. This value is within the healthy range. It has decreased from 1.44 (Mar 24) to 1.41, marking a decrease of 0.03.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.24. This value is within the healthy range. It has increased from 1.21 (Mar 24) to 5.24, marking an increase of 4.03.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 15.42. This value is below the healthy minimum of 20. It has increased from 10.57 (Mar 24) to 15.42, marking an increase of 4.85.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 11.57. This value is below the healthy minimum of 20. It has increased from 8.25 (Mar 24) to 11.57, marking an increase of 3.32.
- For Earning Retention Ratio (%), as of Mar 25, the value is 84.58. This value exceeds the healthy maximum of 70. It has decreased from 89.43 (Mar 24) to 84.58, marking a decrease of 4.85.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 88.43. This value exceeds the healthy maximum of 70. It has decreased from 91.75 (Mar 24) to 88.43, marking a decrease of 3.32.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.35. This value is within the healthy range. It has decreased from 6.00 (Mar 24) to 5.35, marking a decrease of 0.65.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.38. This value is within the healthy range. It has decreased from 3.64 (Mar 24) to 3.38, marking a decrease of 0.26.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,419.92. It has decreased from 2,092.17 (Mar 24) to 1,419.92, marking a decrease of 672.25.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.50. This value exceeds the healthy maximum of 3. It has decreased from 5.48 (Mar 24) to 3.50, marking a decrease of 1.98.
- For EV / EBITDA (X), as of Mar 25, the value is 26.43. This value exceeds the healthy maximum of 15. It has decreased from 37.19 (Mar 24) to 26.43, marking a decrease of 10.76.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.33. This value exceeds the healthy maximum of 3. It has decreased from 5.28 (Mar 24) to 3.33, marking a decrease of 1.95.
- For Retention Ratios (%), as of Mar 25, the value is 84.57. This value exceeds the healthy maximum of 70. It has decreased from 89.42 (Mar 24) to 84.57, marking a decrease of 4.85.
- For Price / BV (X), as of Mar 25, the value is 3.35. This value exceeds the healthy maximum of 3. It has decreased from 5.34 (Mar 24) to 3.35, marking a decrease of 1.99.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.33. This value exceeds the healthy maximum of 3. It has decreased from 5.28 (Mar 24) to 3.33, marking a decrease of 1.95.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Themis Medicare Ltd:
- Net Profit Margin: 5.89%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.13% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 7.41% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.38
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.41
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 53.07)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.2
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 5.89%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot No.69-A, GIDC Industrial Estate, Valsad District Gujarat 396195 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Dinesh S Patel | Chairman & Executive Director |
| Dr. Sachin D Patel | Managing Director & CEO |
| Mr. Rajneesh K Anand | Non Executive Director |
| Dr. Adam Demeter | Non Executive Director |
| Ms. Manjul Sandhu | Independent Director |
| Mr. Bhaskar V Iyer | Independent Director |
| Mr. Nikunt K Raval | Independent Director |
| Ms. Neha Thakore | Independent Director |
| Mr. Shishir V Dalal | Independent Director |
| Mrs. Reena S Patel | Alternate Director |
FAQ
What is the intrinsic value of Themis Medicare Ltd?
Themis Medicare Ltd's intrinsic value (as of 26 December 2025) is 38.10 which is 63.01% lower the current market price of 103.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 948 Cr. market cap, FY2025-2026 high/low of 284/98.0, reserves of ₹371 Cr, and liabilities of 582 Cr.
What is the Market Cap of Themis Medicare Ltd?
The Market Cap of Themis Medicare Ltd is 948 Cr..
What is the current Stock Price of Themis Medicare Ltd as on 26 December 2025?
The current stock price of Themis Medicare Ltd as on 26 December 2025 is 103.
What is the High / Low of Themis Medicare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Themis Medicare Ltd stocks is 284/98.0.
What is the Stock P/E of Themis Medicare Ltd?
The Stock P/E of Themis Medicare Ltd is .
What is the Book Value of Themis Medicare Ltd?
The Book Value of Themis Medicare Ltd is 41.3.
What is the Dividend Yield of Themis Medicare Ltd?
The Dividend Yield of Themis Medicare Ltd is 0.49 %.
What is the ROCE of Themis Medicare Ltd?
The ROCE of Themis Medicare Ltd is 10.4 %.
What is the ROE of Themis Medicare Ltd?
The ROE of Themis Medicare Ltd is 7.65 %.
What is the Face Value of Themis Medicare Ltd?
The Face Value of Themis Medicare Ltd is 1.00.